ClinicalTrials.gov

History of Changes for Study: NCT05414123
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide (FORESEE)
Latest version (submitted September 7, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 June 9, 2022 None (earliest Version on record)
2 September 7, 2022 Recruitment Status, Study Status, Contacts/Locations and Eligibility
Comparison Format:

Scroll up to access the controls

Study NCT05414123
Submitted Date:  June 9, 2022 (v1)

Open or close this module Study Identification
Unique Protocol ID: BIOC-046
Brief Title: A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide (FORESEE)
Official Title: A Longitudinal Therapy Response Monitoring Study in Subjects With Leptomeningeal Metastases Using CNSide (CSF Tumor Cells) Compared to Standard of Care (CSF Cytology, Clinical Evaluation, and Imaging).
Secondary IDs:
Open or close this module Study Status
Record Verification: June 2022
Overall Status: Not yet recruiting
Study Start: July 1, 2022
Primary Completion: July 1, 2024 [Anticipated]
Study Completion: January 1, 2025 [Anticipated]
First Submitted: June 8, 2022
First Submitted that
Met QC Criteria:
June 9, 2022
First Posted: June 10, 2022 [Actual]
Last Update Submitted that
Met QC Criteria:
June 9, 2022
Last Update Posted: June 10, 2022 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Biocept, Inc.
Responsible Party: Sponsor
Collaborators: ICON plc
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). Standard of Care methods to diagnose, or assess the treatment response of LM (Clinical Evaluation, MRI and Cytology) have limited sensitivity and specificity. This creates challenges for physicians to manage LM or determine the best course of treatment. CNSide, is a Laboratory Developed Test (LDT ) that is used commercially at the Physician's discretion in Biocept's CLIA certified, CAP accredited laboratory. CNSide can detect and quantify tumor cells in the CSF from patients with Breast Cancer or NSCLC having a suspicious or confirmed LM. The goal of the FORESEE Study is to evaluate the performance of CNSide in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by Physicians.
Detailed Description: The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). LM is a devastating complication of breast cancer and NSCLC and is diagnosed via clinical evaluation, MRI (with and without contrast of the brain and spine), and CSF Cytology. These methods have limited sensitivity and specificity. Furthermore, they lack the ability to quantitatively measure the LM's response to treatment. These hindrances create challenges for physicians to manage LM or to determine the best course of treatment. CNSide, is a Laboratory Developed Test (LDT ) that is analytically validated and run commercially in Biocept's CLIA certified, CAP accredited laboratory at the Physician's discretion. CNSide can detect and quantify tumor cells in the CSF from patients with Breast Cancer or NSCLC having a suspicious or confirmed LM. Data derived from case studies suggest that the detection of tumor cells in the CSF by CNSide can be used by Physicians to monitor the response of the LM tumor to treatment and improve the ability to make treatment decisions in patients with LM. Subjects enrolled onto the trial will be treated per Standard of Care. The diagnostic tests used to either diagnose LM, or monitor the LMs response to treatment will be Standard of Care, in combination with CNSide. The goal of the FORESEE Study is to further evaluate the performance of CNSide for LM in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by Physicians.
Open or close this module Conditions
Conditions: Leptomeningeal Metastasis
Leptomeningeal Disease
Leptomeningeal Neoplasms
Breast Cancer
Non-Small Cell Lung Cancer
Keywords: Leptomeningeal Metastasis
Cerebro-Spinal Fluid
Liquid Biopsy
Tumor Cells
Open or close this module Study Design
Study Type: Observational
Observational Study Model: Cohort
Time Perspective: Prospective
Biospecimen Retention:
Biospecimen Description:
Enrollment: 40 [Anticipated]
Number of Groups/Cohorts 2
Open or close this module Groups and Interventions
Groups/Cohorts Interventions
Breast Cancer
Subjects with Breast Cancer of all subtypes and independent of Hormone status who have a confirmed or suspicious Leptomeningeal Metastasis by Investigator assessment of radiographic image and clinical evaluation and cytology
Device: CNSide
The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
Non-Small Cell Lung Cancer
Subjects with Non-Small Cell Lung Cancer of all subtypes who have a confirmed or suspicious Leptomeningeal Metastasis by Investigator assessment of radiographic image and clinical evaluation and cytology
Device: CNSide
The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Assess the impact of CNSide on treatment decisions
[ Time Frame: 1 year ]

The proportion of decision points during LM treatment in which the physician indicated that CNSide aided in their decision making.
Secondary Outcome Measures:
1. Evaluate CNSide as a treatment response monitoring device for LM tumors
[ Time Frame: 2 years ]

The correlation of changes in tumor cell number throughout treatment with clinical evaluation, cytology, and radiographic results.
2. The performance of CNSide of tumor cell detection in the CSF compared to cytology
[ Time Frame: 2 years ]

The comparison of the sensitivity, specificity, PPV and NPV of CNSide to cytology in detection of tumor cells in the CSF (Cytology being the reference standard)
Open or close this module Eligibility
Study Population: The subjects will be selected from all clinics where subjects having Breast Cancer or Non-Small Cell Lung Cancer having a suspicious or confirmed LM are being diagnosed or treated by Physicians.
Sampling Method: Non-Probability Sample
Minimum Age:
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  1. Subjects > 18 years of age
  2. All genders, races, or ethnic groups,
  3. Diagnosed with Breast Cancer or NSCLC who present with clinically suspected LM based on Investigator assessment of radiographic image, cytology, and clinical evaluation.
  4. Cytology positive and negative subjects will be included.
  5. Subjects willing to provide an Informed Consent.
  6. Subjects willing and able to undergo CSF or blood collection via Lumbar Puncture and Ommaya Reservoir as well as veni-puncture and shunt.
  7. Both patients with and without parenchymal brain metastases will be eligible as long as leptomeningeal metastases are suspected
  8. Subjects who previously had a diagnosis of Leptomeningeal Disease by Investigator assessment of radiographic image and clinical evaluation and cytology.

Exclusion Criteria:

  1. Subjects who do not have cancer,
  2. Subjects with other types of tumors than breast or lung cancer
  3. Subjects diagnosed with a primary brain tumor
  4. Subjects who are unable to undergo lumbar puncture, a shunt or veni-puncture.
  5. Lack of suspicious LM based in imaging or clinical evaluation.
  6. Ordering the Commercial CNSide test while subject is on study
  7. Pregnant women and adults lacking capacity to consent for themselves
Open or close this module Contacts/Locations
Central Contact Person: Barbara Blouw, PhD
Telephone: 858-320-8200 Ext. 208
Email: bblouw@biocept.com
Central Contact Backup: David Isley, PhD
Telephone: 858-223-0649 Ext. 374
Email: disley@biocept.com
Study Officials: Priya Kumthekar, MD
Principal Investigator
Northwestern University Medical Center
Locations:
Open or close this module IPDSharing
Plan to Share IPD: No
There is no plan to make the IDP available to other researchers.
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services